Effectiveness of Adjuvant Therapy in Patients with Pancreatic Cancer Who Underwent Neoadjuvant Therapy.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
25
08
2020
accepted:
26
01
2021
pubmed:
20
2
2021
medline:
28
9
2021
entrez:
19
2
2021
Statut:
ppublish
Résumé
Neoadjuvant therapy (NAT) is used to treat not only advanced pancreatic cancer but also resectable lesions. The present study investigated the effectiveness of postoperative adjuvant chemotherapy for patients with pancreatic cancer who underwent surgical resection after NAT. Patients who underwent macroscopically curative resection after NAT for pancreatic cancer were enrolled. Adjuvant chemotherapy was defined as at least 1 cycle of planned chemotherapy within 3 months after the date of surgery and included S-1, gemcitabine, or both. We retrospectively examined the effect of adjuvant chemotherapy on overall survival (OS) and recurrence-free survival (RFS) as a function of patients' clinicopathological factors. Ninety-seven patients were included in the study, of which 68 (70.1%) underwent adjuvant chemotherapy. Administration of adjuvant chemotherapy was significantly associated with prolonged OS and RFS in patients whose elevated levels of carbohydrate antigen 19-9 or duke pancreatic monoclonal antigen type-2 did not normalize after NAT. In patients with pathological lymph node metastasis, the administration of adjuvant chemotherapy was significantly associated with longer OS but did not improve PFS. Postoperative adjuvant chemotherapy was associated with prolonged postoperative survival in patients with pancreatic cancer who did not sufficiently respond to NAT as judged by tumor marker expression.
Identifiants
pubmed: 33606140
doi: 10.1245/s10434-021-09712-6
pii: 10.1245/s10434-021-09712-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6238-6245Subventions
Organisme : Japan Society for the Promotion of Science
ID : a Grants-in-Aid for Scientific Research (18K08626)
Informations de copyright
© 2021. Society of Surgical Oncology.
Références
Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1–7.
doi: 10.1016/S1072-7515(99)00075-7
Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908–15.
doi: 10.1038/sj.bjc.6605256
Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.
doi: 10.1001/jama.2013.279201
Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.
doi: 10.1016/S0140-6736(16)30583-9
Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–24.
doi: 10.1016/S0140-6736(16)32409-6
Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406.
doi: 10.1056/NEJMoa1809775
Altman AM, Wirth K, Marmor S, et al. Completion of adjuvant chemotherapy after upfront surgical resection for pancreatic cancer is uncommon yet associated with improved survival. Ann Surg Oncol. 2019;26:4108–16.
doi: 10.1245/s10434-019-07602-6
Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261:12–7.
doi: 10.1097/SLA.0000000000000867
Rose JB, Rocha FG, Alseidi A, et al. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol. 2014;21:1530–7.
doi: 10.1245/s10434-014-3486-z
Kurahara H, Shinchi H, Ohtsuka T, et al. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study.Langenbecks Arch Surg. 2019;404:167–74.
doi: 10.1007/s00423-019-01754-5
Nagakawa Y, Sahara Y, Hosokawa Y, et al. Clinical impact of neoadjuvant chemotherapy and chemoradiotherapy in borderline resectable pancreatic cancer: analysis of 884 patients at facilities specializing in pancreatic surgery.Ann Surg Oncol. 2019;26:1629–36.
doi: 10.1245/s10434-018-07131-8
Eguchi H, Takeda Y, Takahashi H, et al. A Prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2019;26:4498–505.
doi: 10.1245/s10434-019-07735-8
Motoi F, Kosuge T, Ueno H, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019;49:190–4.
doi: 10.1093/jjco/hyy190
Barbour AP, Samra JS, Haghighi KS, et al. The AGITG GAP Study: A phase II study of perioperative gemcitabine and nab-paclitaxel for resectable pancreas cancer. Ann Surg Oncol. 2020;27:2506–15.
doi: 10.1245/s10434-020-08205-2
Katz MH, Pisters PW, Lee JE, Fleming JB. Borderline resectable pancreatic cancer: what have we learned and where do we go from here? Ann Surg Oncol. 2011;18:608–10.
doi: 10.1245/s10434-010-1460-y
Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19–9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012;3:105–19.
pubmed: 22811878
pmcid: 3397644
Paniccia A, Hosokawa P, Henderson W, et al. Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma. JAMA Surg. 2015;150:701–10.
doi: 10.1001/jamasurg.2015.0668
Qiu M, Qiu H, Jin Y, et al. Pathologic diagnosis of pancreatic adenocarcinoma in the United States: Its status and prognostic value. J Cancer. 2016;7:694–701.
doi: 10.7150/jca.14185
Kurahara H, Maemura K, Mataki Y, et al. A therapeutic strategy for resectable pancreatic cancer based on risk factors of early recurrence. Pancreas. 2018;47:753–8.
doi: 10.1097/MPA.0000000000001066
Kurahara H, Maemura K, Mataki Y, et al. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma. Pancreatology. 2016;16:1051–6.
doi: 10.1016/j.pan.2016.09.014
Sunagawa Y, Yamada S, Sato Y, et al. Novel prognostic implications of DUPAN-2 in the era of initial systemic therapy for pancreatic cancer. Ann Surg Oncol. 2020;27:2081–9.
doi: 10.1245/s10434-019-07981-w
Aoki S, Motoi F, Murakami Y, et al. Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. BMC Cancer. 2019;19:252.
doi: 10.1186/s12885-019-5460-4
Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma version NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:1028–61.
doi: 10.6004/jnccn.2017.0131
Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC Cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018;25:845–7.
doi: 10.1245/s10434-017-6025-x
Shinchi H, Maemura K, Mataki Y, et al. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. J Hepatobiliary Pancreat Sci. 2012;19:152–8.
doi: 10.1007/s00534-011-0400-y
Motoi F, Ishida K, Fujishima F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol. 2013;20:3794–801.
doi: 10.1245/s10434-013-3129-9
Park JK, Paik WH, Ryu JK, et al. Clinical significance and revisiting the meaning of CA 19–9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution. PLoS One. 2013;8:e78977.
doi: 10.1371/journal.pone.0078977
Kawa S, Tokoo M, Oguchi H, et al. Epitope analysis of SPan-1 and DUPAN-2 using synthesized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose. Pancreas. 1994;9:692–7.
doi: 10.1097/00006676-199411000-00003
van Roessel S, van Veldhuisen E, Klompmaker S, et al. Evaluation of adjuvant chemotherapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX treatment. JAMA Oncol. 2020. https://doi.org/10.1001/jamaoncol.2020.3537 .
doi: 10.1001/jamaoncol.2020.3537
pubmed: 32910170
pmcid: 7489392